A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Sponsor
Hoosier

Protocol Number
CRN GU16-260

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910

A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma